Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
默克默克(US:MRK) Businesswire·2026-04-02 18:50

文章核心观点 - 提供的文档内容仅为网页的页脚信息，包含公司名称“Akamai”及其“Powered and protected by”和“Privacy”的标识，未包含任何实质性的新闻、事件、财报或业务内容 [1] 根据相关目录分别进行总结 - 文档内容不涉及任何具体的行业动态、公司财务数据、运营状况、市场表现或战略信息 [1] - 文档内容不包含任何可用于分析的投资机会或风险的具体细节 [1]

Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration - Reportify